Zobrazeno 1 - 10
of 247
pro vyhledávání: '"Hans Prenen"'
Autor:
Laure-Anne Teuwen, Joanna Young, Saleh Alessy, Berna C. Özdemir, Diah Martina, Sharif Folorunso, Maria T. Bourlon, Hans Prenen, Eva Segelov
Publikováno v:
JCO Global Oncology, Iss 10 (2024)
PURPOSEMultiple disparities have been recognized in the area of location, gender, and funding for leadership in oncology clinical trials. Understanding their intersectionality is crucial to be able to formulate policies and actions, to ensure researc
Externí odkaz:
https://doaj.org/article/2721b36d7b2d4bfeb1fe2412bc9a3718
Autor:
Christophe Deben, Laurie Freire Boullosa, Felicia Rodrigues Fortes, Edgar Cardenas De La Hoz, Maxim Le Compte, Sofie Seghers, Marc Peeters, Steve Vanlanduit, Abraham Lin, Krijn K. Dijkstra, Paul Van Schil, Jeroen M. H. Hendriks, Hans Prenen, Geert Roeyen, Filip Lardon, Evelien Smits
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-15 (2024)
Abstract Background This study explores the repurposing of Auranofin (AF), an anti-rheumatic drug, for treating non-small cell lung cancer (NSCLC) adenocarcinoma and pancreatic ductal adenocarcinoma (PDAC). Drug repurposing in oncology offers a cost-
Externí odkaz:
https://doaj.org/article/8c03f6975c524c59adae79b1d8c7f709
Autor:
Maxim Le Compte, Edgar Cardenas De La Hoz, Sofía Peeters, Felicia Rodrigues Fortes, Christophe Hermans, Andreas Domen, Evelien Smits, Filip Lardon, Timon Vandamme, Abraham Lin, Steve Vanlanduit, Geert Roeyen, Steven Van Laere, Hans Prenen, Marc Peeters, Christophe Deben
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-14 (2023)
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, characterized by a treatment-resistant and invasive nature. In line with these inherent aggressive characteristics, only a subset of patients shows a clinical respon
Externí odkaz:
https://doaj.org/article/6632e8a47737498b80b21ca813df1b57
Autor:
Denise van der Graaff, Sofie Seghers, Pieterjan Vanclooster, Christophe Deben, Timon Vandamme, Hans Prenen
Publikováno v:
Cancers, Vol 16, Iss 15, p 2671 (2024)
Colorectal cancer (CRC) remains a significant health burden globally, being the second leading cause of cancer-related mortality. Despite significant therapeutic advancements, resistance to systemic antineoplastic agents remains an important obstacle
Externí odkaz:
https://doaj.org/article/49e97c3a46624b2cb89e0fa849986442
Autor:
Danielle Delombaerde, Christof Vulsteke, Nico Van de Veire, Delphine Vervloet, Veronique Moerman, Lynn Van Calster, Anne-Marie Willems, Lieselot Croes, Félix Gremonprez, Astrid De Meulenaere, Ximena Elzo Kraemer, Kristien Wouters, Marc Peeters, Hans Prenen, Johan De Sutter
Publikováno v:
Pharmaceuticals, Vol 17, Iss 7, p 965 (2024)
Background: There is an unmet medical need for the early detection of immune checkpoint inhibitor (ICI)-induced cardiovascular (CV) adverse events due to a lack of adequate biomarkers. This study aimed to provide insights on the incidence of troponin
Externí odkaz:
https://doaj.org/article/5c2974b35ed74f08a578e0745f94e7c5
Autor:
Andreas Domen, Christophe Deben, Jasper Verswyvel, Tal Flieswasser, Hans Prenen, Marc Peeters, Filip Lardon, An Wouters
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-35 (2022)
Abstract Cellular senescence is a state of stable cell-cycle arrest with secretory features in response to cellular stress. Historically, it has been considered as an endogenous evolutionary homeostatic mechanism to eliminate damaged cells, including
Externí odkaz:
https://doaj.org/article/b64cfeae058642f8a5d74c8b1aeb8c07
Autor:
Danielle Delombaerde, Delphine Vervloet, Dieter Berwouts, Roel Beckers, Hans Prenen, Marc Peeters, Félix Gremonprez, Lieselot Croes, Christof Vulsteke
Publikováno v:
Journal of Medical Case Reports, Vol 16, Iss 1, Pp 1-7 (2022)
Abstract Background Myocarditis in patients treated with immune checkpoint inhibitors has previously been reported to be rare, though it has most likely been underreported owing to misdiagnosis in the absence of overt clinical presentation. Early det
Externí odkaz:
https://doaj.org/article/933f89ec8e074962810be6077ed54c7f
Publikováno v:
Diagnostics, Vol 13, Iss 9, p 1619 (2023)
Next-generation sequencing (NGS) can be used to detect tumor-specific genomic alterations. This retrospective single-center study aims to assess the application of an extensive NGS panel to identify actionable alterations and initiate matched targete
Externí odkaz:
https://doaj.org/article/3ba29aae21a2449b854e10def7befe6e
Autor:
Danielle Delombaerde, Johan De Sutter, Lieselot Croes, Delphine Vervloet, Veronique Moerman, Nico Van de Veire, Anne-Marie Willems, Kristien Wouters, Marc Peeters, Hans Prenen, Christof Vulsteke
Publikováno v:
Pharmaceuticals, Vol 16, Iss 4, p 625 (2023)
Background: The increasing use of immune checkpoint inhibitors (ICIs) in the treatment of both advanced and early stages of various malignancies has resulted in a substantial increase in the incidence of cardiovascular (CV) immune-related adverse eve
Externí odkaz:
https://doaj.org/article/97d08a5ebfab4110a55325461b799ba7
Autor:
Eva Segelov, Hans Prenen, Daphne Day, C. Raina Macintyre, Estelle Mei Jye Foo, Raghib Ali, Quanyi Wang, Xiaoting Wei, Gilberto de Lima Lopes, Kefeng Ding, Gong Chen, John Whay Kuang Chia, Han Chong Toh
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 585-588 (2020)
Externí odkaz:
https://doaj.org/article/54db7ec56ed34fa699baf42e80a421a6